Press Releases September 3, 2026 08:00 AM

InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference

InspireMD to Present at H.C. Wainwright 28th Annual Global Investment Conference

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
NSPR

InspireMD, Inc. announced it will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026. The company develops the CGuard® Prime carotid stent system aimed at stroke prevention and will provide a live webcast of the presentation.

InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference
NSPR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • InspireMD is showcasing its CGuard® Prime carotid stent system technology to investors at a significant global investment conference.
  • The company emphasizes its proprietary MicroNet™ mesh technology designed to improve carotid stenting outcomes and reduce stroke risk.
  • The presentation could increase investor awareness and interest in InspireMD's stroke prevention medical devices, impacting the healthcare and medical devices sector.

MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14th at 2:30 pm Eastern Time (ET).

A live audio webcast and an archive of the recording will be available through the investors page of InspireMD’s corporate website at https://investors.inspiremd.com.

To request a meeting or for more details about the conferences, please reach out to your institutional contact.

About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free long-term outcomes. InspireMD’s common stock is quoted on Nasdaq under the ticker symbol NSPR. We routinely post information that may be important to investors on the Company’s website. For more information, please visit www.inspiremd.com.

Investor Contacts:
Jeff Warren
LifeSci Advisors
[email protected]
[email protected]


Risks

  • Market adoption and regulatory approval challenges for the CGuard® Prime carotid stent system could affect company growth.
  • Competition within the medical device sector for stroke prevention technologies may impact InspireMD's market share.
  • Future financial performance is uncertain and will depend on clinical success, reimbursement, and broader economic healthcare spending trends.

More from Press Releases

Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call Sep 6, 2026 Verizon Waives Charges for Hurricane Lowell, Prepares Network in Hawai'i Sep 5, 2026 Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen Sep 4, 2026 Grupo Aeroportuario del Pacifico Reports a Passenger Traffic Increase in August 2026 of 0.5% Compared to 2025 Sep 4, 2026 Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference Sep 4, 2026